Skip to main content

Advertisement

Table 1 Distribution of RAS-BRAF mutations according to the characteristics of CRC patients

From: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study

Characteristic No. % KRAS mut NRAS mut BRAF mut All mut
Sex
Male 772 60.1 253 (32.8 %) 31 (4.0 %) 13 (1.7 %) 297 (39.8 %)
Female 512 39.9 204 (39.8 %) 22 (4.3 %) 14 (2.7 %) 240 (46.9 %)
Anatomical tumour site
Right-transverse colon 441 34.3 148 (35.6 %) 18 (4.1 %) 9 (2.0 %) 175 (39.7 %)
Left colon 516 40.2 185 (35.9 %) 21 (4.1 %) 10 (1.9 %) 216 (41.9 %)
Rectum 327 25.5 124 (37.9 %) 14 (4.3 %) 8 (2.4 %) 146 (44.6 %)
Disease stage at diagnosis
Stage II (T3–4N0M0) 286 22.3 108 (37.8 %) 11 (3.8 %) 6 (2.1 %) 125 (43.7 %)
Stage III (TXN1–3M0) 567 44.1 191 (33.7 %) 24 (4.2 %) 9 (1.6 %) 224 (39.5 %)
Stage IV (TXNXM1) 431 33.6 158 (36.7 %) 18 (4.2 %) 12 (2.8 %) 188 (43.6 %)
Tumour grading
Well differentiated 138 10.7 49 (35.5 %) 7 (5.1 %) 3 (2.2 %) 59 (42.8 %)
Moderately differentiated 1041 81.1 370 (35.5 %) 41 (3.9 %) 21 (2.0 %) 432 (41.5 %)
Poorly differentiated 105 8.2 38 (36.2 %) 5 (4.8 %) 3 (2.9 %) 46 (43.8 %)
Age, years
≤50 126 9.8 47 (37.3 %) 10 (7.9 %) 3 (2.4 %) 60 (47.6 %)
51–60 325 25.3 118 (36.3 %) 12 (3.7 %) 6 (1.8 %) 136 (41.8 %)
61–70 492 38.3 173 (35.2 %) 19 (3.9 %) 9 (1.8 %) 201 (40.9 %)
>70 341 26.6 119 (34.9 %) 12 (3.5 %) 9 (2.6 %) 140 (41.1 %)